The real cost of pediatric Crohn's disease: the role of infliximab in the treatment of pediatric IBD

Am J Gastroenterol. 2003 Apr;98(4):717-20. doi: 10.1111/j.1572-0241.2003.07396.x.
No abstract available

Publication types

  • Comment
  • Editorial

MeSH terms

  • Age Factors
  • Antibodies, Monoclonal / economics*
  • Antibodies, Monoclonal / therapeutic use*
  • Child
  • Cost of Illness*
  • Crohn Disease / complications*
  • Crohn Disease / drug therapy*
  • Crohn Disease / economics
  • Drug Costs
  • Gastrointestinal Agents / economics*
  • Gastrointestinal Agents / therapeutic use*
  • Growth Disorders / economics
  • Growth Disorders / etiology*
  • Growth Disorders / prevention & control*
  • Humans
  • Infliximab

Substances

  • Antibodies, Monoclonal
  • Gastrointestinal Agents
  • Infliximab